首页> 外文期刊>中草药:英文版 >Combination therapy of tripterygium glycosides plus valsartan in diabetic nephropathy treatment: A systematic review and meta-analysis
【24h】

Combination therapy of tripterygium glycosides plus valsartan in diabetic nephropathy treatment: A systematic review and meta-analysis

机译:雷公藤多甙联合缬沙坦治疗糖尿病肾病的系统评价与荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To assess the efficacy and safety of the combination therapy of Chinese herbal medicines,tripterygium glycosides, plus valsartan for the treatment of diabetic nephropathy(DN).Methods: A comprehensive research of 12 electronic databases was performed. Data of the included studies were extracted and analyzed independently by two authors, and were synthesized using Review Manager(version 5.2) and Stata(version 12.0).Results: A total of 12 randomized controlled trials(RCTs) involving 829 patients were included. Pooled results showed that the combination therapy significantly increased total efficacy of DN patients [RR = 1.35,95% CI(1.22, 1.50), P < 0.001], the level of serum albumin [Mean difference(MD)= 3.87, 95% CI(3.12,4.62), P < 0.001], and significantly decreased 24 h urinary protein level [MD =-0.97, 95% CI(-1.19,-0.76), P < 0.001], urinary albumin-excretion rate [MD =-145.53, 95% CI(-227.95,-63.11), P < 0.001],and urinary β2-microglobuli level [MD =-11.86, 95% CI(-13.02,-10.69), P < 0.001]. No significant differences were found in levels of serum creatinine [MD =-0.26, 95% CI(-7.52, 7.00), P > 0.05), blood urea nitrogen [MD = 0.25, 95% CI(-0.23, 0.74), P > 0.05], and endogenous creatinine clearance rate[MD =-0.43, 95% CI(-3.48, 2.62), P > 0.05]. However, tripterygium glycosides plus valsartan seemed to exert higher adverse reaction rate than valsartan monotherapy [MD = 3.41, 95% CI(1.34, 8.66), P < 0.05].There were no publication bias for all of the pooled effect sizes.Conclusion: Combination therapy of tripterygium glycosides plus valsartan may be effective for the treatment of DN. However, the safety of the combination therapy need to be further confirmed.
机译:目的:评价雷公藤多甙,缬沙坦联合治疗糖尿病肾病的疗效和安全性。方法:对12个电子数据库进行了综合研究。纳入研究的数据由两位作者独立提取和分析,并使用Review Manager(版本5.2)和Stata(版本12.0)进行了综合。结果:共纳入12项涉及829例患者的随机对照试验(RCT)。汇总结果显示,联合治疗显着提高了DN患者的总疗效[RR = 1.35,95%CI(1.22,1.50),P <0.001],血清白蛋白水平[平均差异(MD)= 3.87,95%CI (3.12,4.62),P <0.001],并显着降低24小时尿蛋白水平[MD = -0.97,95%CI(-1.19,-0.76),P <0.001],尿白蛋白排泄率[MD =- 145.53,95%CI(-227.95,-63.11),P <0.001]和尿中β2-微球水平[MD = -11.86,95%CI(-13.02,-10.69),P <0.001]。血清肌酐水平[MD = -0.26,95%CI(-7.52,7.00),P> 0.05),血尿素氮[MD = 0.25,95%CI(-0.23,0.74),P > 0.05],内源性肌酐清除率[MD = -0.43,95%CI(-3.48,2.62),P> 0.05]。然而,雷公藤多甙加缬沙坦似乎比缬沙坦单药疗法具有更高的不良反应发生率[MD = 3.41,95%CI(1.34,8.66),P <0.05]。所有合并的效应量均无发表偏倚。雷公藤多甙与缬沙坦的联合治疗可能对DN有效。但是,联合治疗的安全性需要进一步证实。

著录项

  • 来源
    《中草药:英文版》 |2019年第2期|P.222-230|共9页
  • 作者单位

    [1]Department of Chemotherapy 2, Wenzhou Central Hospital, Wenzhou 325000, China;

    [2]State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310000, China;

    [3]Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Hangzhou 310000, China;

    [4]Department of Cardiology, The Second Affiliated Hospital, Wenzhou Medical University, Wenzhou 325000, China;

    [5]Zhuang Medical College, Guangxi University of Chinese Medicine, Nanning 530000, China;

    [6]Department of Traditional Chinese Medicine, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou 325000, China;

    [6]Department of Traditional Chinese Medicine, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou 325000, China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 CHI
  • 中图分类 医药、卫生;
  • 关键词

    diabetic nephropathy; meta-analysis; tripterygium glycosides; valsartan;

    机译:糖尿病肾病;荟萃分析;雷公藤多甙;缬沙坦;
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号